Other substances

Fostamatinib

A Syk kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Fostamatinib is a Syk kinase inhibitor with potential anti-inflammatory and immunomodulating properties. The repression of Syk kinase signalling results in inhibition of the activation of immune cells and inflammatory responses leading to tissue damage (NCIt).

Fostamatinib on DrugBank
Fostamatinib on PubChem
Fostamatinib on Wikipedia

Synonyms

R406

Marketed as

TAVALISSE

CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic Preprint Screening	murine lung epithelial cells			Jun/30/2020
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic Small molecule In vitro	Healthy donor neutrophils; COVID-19 ECMO patients' plasma	4.73	The drug in vitro prevented netosis of healthy donors' neutrophils treated with COVID-19 extracorporeal membrane oxygenation patients' plasma at concentrations achievable with standard oral dosing.	Dec/24/2020

AI-suggested references

Link	Publication date
Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial.	Jul/26/2020
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.	Mar/03/2022
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19	Aug/28/2020
Drug repurposing improves disease targeting 11-fold and can be augmented by network module targeting, applied to COVID-19	Oct/19/2021
Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?	Aug/27/2021
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics.	Apr/14/2021
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.	Nov/17/2020
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages	May/11/2021
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.	Oct/29/2020
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a pro-thrombotic stimulus for platelets	May/24/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04629703	Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects	Recruiting	Phase 3	Feb/22/2021	May/01/2022
Alternative id - C-935788-061 Interventions - Drug: Fostamatinib\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - University of California Irvine, Orange, California, United States\|Alternative Research Associates, LLC, Hialeah, Florida, United States\|Alternative Research Associates, LLC, Miami, Florida, United States\|Loyola University Medical School, Maywood, Illinois, United States\|Harvard Medical School- Bringham and Women's Hospital, Boston, Massachusetts, United States\|Ascension Medical Group- St. John Clinic Infectious Disease, Tulsa, Oklahoma, United States\|Providence Portland Medical Center, Portland, Oregon, United States\|Houston Methodist Research Institute, Houston, Texas, United States\|Clinica Chutro, Cordoba, CP, Argentina\|Hospital Lencinas, Godoy Cruz, Mendoza, Argentina\|Corporacion Medica de General San Martin, San Martin, Provincia De Buenos Aires, Argentina\|Hospital de Alta Complejidad Cuenta Alta, Buenos Aires, Argentina\|Hospital Del Bicentenario - Dr. Luis Federico Leloir, Buenos Aires, Argentina\|Clinica Zabala, Buenos Aires, Argentina\|Clinica Adventista Belgrano, Buenos Aires, Argentina\|Clinica Monte Grande, Buenos Aires, Argentina\|Hospital de Infecciosas Dr.Francisco Javier Muñiz, Buenos Aires, Argentina\|Sanatorio Guemes, Buenos Aires, Argentina\|Sanatorio Sagrado Corazon, Buenos Aires, Argentina\|Hospital San Roque, Córdoba, Argentina\|Sanatorio Mayo Privado, Córdoba, Argentina\|Hospital das Clínicas da Universidade Federal de Goiás (HC/UFG), Goiânia, Goiás, Brazil\|Hospital Luxenburgo-Associação Mário Penna, Belo Horizonte, Minas Gerais, Brazil\|Hospital Universitario de Maringa, Maringá, Parana, Brazil\|Hosp. Angelina Caron, Campina Grande do Sul, Paraná, Brazil\|Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA, Porto Alegre, Rio Grande Do Sul, Brazil\|Hospital des clinicas de porto alegre - Centro de pequisas clinicas, Porto Alegre,, RS, Brazil\|Complexo de Prevenção, Diagnóstico, Terapia e Reabilitação Respiratória LTDA, Blumenau, Santa Catarina, Brazil\|Hospital Alemão Oswaldo Cruz (HAOC), Bela Vista, Sao Paolo, Brazil\|Pontificia Universidade Catolica de Campinas (PUC-CAMP) - Hospital e Maternidade Celso Pierro (HMCP), Campinas, Sao Paolo, Brazil\|Hospital Bandeirantes (LeForte), Liberdade, Sao Paolo, Brazil\|Hospital Universitário São Francisco na Providência de Deus, Braganca Paulista, Sao Paulo, Brazil\|Clinica de Alergia Martti Antila S/S Ltda, Sorocaba, Sao Paulo, Brazil\|Fundação Faculdade Reg. de Med de SJRP, São José Do Rio Preto, Sao Paulo, Brazil\|Star Medica Vivo Bicentenario, Nezahualcóyotl, Mex, Mexico\|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo Leon, Mexico\|Köhler & Milstein Research, Mérida, Yucatán, Mexico\|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico\|Nuevo Hospital Civil de Guadalajara, Guadalajara, Mexico\|Centro Medico Issemym Toluca, Metepec, Mexico\|The American British Cowdray Medical Center I.A.P., Mexico City, Mexico\|Hospital Ángeles Roma, Mexico, Mexico\|CEPREP Centro de Prevención y Rehabilitación de Enfermedades Pulmonares Crónicas, Nuevo León, Mexico\|Hospital Civil de Culiacan, Sinaloa, Mexico\|Hospital Civil de Culiacan, Sinaloa, Mexico\|Hospital Militar Central, Jesús María, Lima, Peru\|EsSalud - Hospital Nacional Alberto Sabogal Sologuren, Lima, Peru\|Hospital de Chancay, Lima, Peru\|Hospital Maria Auxiliadora, Lima, Peru\|Hospital Nacional Arzobispo Loayza, Lima, Peru\|Hospital Nacional Cayetano Heredia, Lima, Peru\|Hospital Nacional Hipolito Unanue, Lima, Peru Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 308 Age - 18 Years to 100 Years (Adult, Older Adult) Outcome measures - Progression to severe/critical disease within 29 days of first dose of study treatment\|Proportion of subjects transferred into the intensive care unit (ICU) or who died by Day 29
NCT04579393	Fostamatinib for Hospitalized Adults With COVID-19	Completed	Phase 2	Oct/08/2020	Apr/30/2021
Alternative id - 10000110\|000110-H Interventions - Drug: Placebo\|Drug: fostamatinib Study type - Interventional Study results - Has Results Locations - National Institutes of Health Clinical Center, Bethesda, Maryland, United States\|INOVA Health Systems, Falls Church, Virginia, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 59 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Number of Participants With at Least 1 Serious Adverse Event\|Number of Participants With Sustained Recoveries Defined by Ordinal Scale Score of 3 or Less\|Number of Participants Who Progress to Mechanical Ventilation\|Number of Participants With Cumulative Clinical Endpoint of Death\|Number of Grade 3 and 4 Adverse Events Through Day 60\|Participant Score on Ordinal Scale\|Change in C-Reactive Protein Levels From Baseline\|Change in Fibrinogen Levels From Baseline.\|Change in D-Dimer Levels From Baseline\|Change in Ferritin Levels From Baseline\|Change in Interleukin 6 (IL6) Levels From Baseline\|Median Days Participants Were Admitted to Intensive Care Unit\|Relative Change in SpO2/FiO2 Ratio\|Change in SOFA Score From Baseline\|Median Days on Participants Received Supplemental Oxygen\|The Number of Participants That Experienced Acute Renal Failure\|Number of Participants That Experienced a Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)\|Change in Absolute Lymphocyte Count Levels From Baseline\|Change in Absolute Neutrophil Count Levels From Baseline\|Change in Platelet Count Levels From Baseline
NCT04924660	Novel Experimental COVID-19 Therapies Affecting Host Response	Recruiting	Phase 2\|Phase 3	Jul/15/2021	Apr/15/2023
Alternative id - 210982 Interventions - Drug: TXA127\|Drug: TRV027\|Drug: Placebo\|Drug: Fostamatinib Study type - Interventional Study results - No Results Available Locations - University of Alabama Birmingham, Birmingham, Alabama, United States\|Chandler Regional Medical Center, Chandler, Arizona, United States\|Los Angeles County University of Southern California Medical Center, Los Angeles, California, United States\|University of Southern California, Los Angeles, California, United States\|Cedars-Sinai Medical Center, Los Angeles, California, United States\|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States\|UCSF Medical Center - Parnassus, San Francisco, California, United States\|Stanford University, Stanford, California, United States\|University of Colorado Hospital, Aurora, Colorado, United States\|Denver Health Medical Center, Denver, Colorado, United States\|Yale University, New Haven, Connecticut, United States\|University of Florida, Gainesville, Florida, United States\|University of Florida, Jacksonville, Jacksonville, Florida, United States\|Public Health Trust of Miami-Dade County, Florida - Jackson Memorial Hospital, Miami, Florida, United States\|Ponce de Leon Clinical Research Site, Atlanta, Georgia, United States\|Emory Johns Creek, Atlanta, Georgia, United States\|Emory St. Joseph's Hospital, Atlanta, Georgia, United States\|University of Illinois at Chicago, Chicago, Illinois, United States\|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States\|AMITA Health St. Alexius Medical Center, Hoffman Estates, Illinois, United States\|University of Kentucky, Lexington, Kentucky, United States\|Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States\|Ochsner Clinic Foundation, New Orleans, Louisiana, United States\|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States\|Johns Hopkins University, Baltimore, Maryland, United States\|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States\|Massachusetts General Hospital, Boston, Massachusetts, United States\|Brigham and Women's Hospital, Boston, Massachusetts, United States\|Newton-Wellesley Hospital, Newton, Massachusetts, United States\|Baystate Health, Springfield, Massachusetts, United States\|University of Michigan, Ann Arbor, Michigan, United States\|Detroit Receiving Hospital, Detroit, Michigan, United States\|DMC Detroit Receiving Hospital, Detroit, Michigan, United States\|Sinai-Grace Hospital, Detroit, Michigan, United States\|University of Minnesota Fairview Southdale, Edina, Minnesota, United States\|Hennepin County Medical Center, Minneapolis, Minnesota, United States\|University of Minnesota Medical Center, Minneapolis, Minnesota, United States\|University of Mississippi Medical Center, Jackson, Mississippi, United States\|Washington University, Saint Louis, Missouri, United States\|University of Nebraska Medical Center, Omaha, Nebraska, United States\|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States\|Montefiore Medical Center Weiler Campus, Bronx, New York, United States\|Montefiore Medical Center Moses Campus, Bronx, New York, United States\|Columbia University Irving Medical Center, New York, New York, United States\|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States\|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States\|Cleveland Clinic Akron General, Akron, Ohio, United States\|University of Cincinnati, Cincinnati, Ohio, United States\|Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States\|Cleveland Clinic Foundation, Cleveland, Ohio, United States\|Cleveland Clinic Marymount Hospital, Garfield Heights, Ohio, United States\|Cleveland Clinic Hillcrest Hospital, Mayfield Heights, Ohio, United States\|Oregon Health & Science University, Portland, Oregon, United States\|Temple University Hospital, Philadelphia, Pennsylvania, United States\|Thomas Jefferson University, Philadelphia, Pennsylvania, United States\|Medical University of South Carolina, Charleston, South Carolina, United States\|Vanderbilt University Medical Center, Nashville, Tennessee, United States\|Tennessee Valley Healthcare System- Nashville, Nashville, Tennessee, United States\|UT Southwestern Medical Center, Dallas, Texas, United States\|University of Texas, Houston, Houston, Texas, United States\|Intermountain Medical Center, Murray, Utah, United States\|University of Utah Health, Salt Lake City, Utah, United States\|UVA Health, Charlottesville, Virginia, United States\|VCU Health, Richmond, Virginia, United States\|Harborview Medical Center/University of Washington, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 1600 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Oxygen free days through day 28.\|In-hospital mortality\|Alive and oxygen free at Day 14\|Alive and oxygen free at Day 28\|Alive and free of new invasive mechanical ventilation at day 28\|28-day mortality\|60-day mortality\|90-day mortality\|Clinical status assessed using World Health Organization (WHO) 8-point ordinal scale at Day 14\|Clinical status assessed using WHO 8-point ordinal scale at Day 28\|Clinical status assessed using WHO 8-point ordinal scale at Day 60\|Hospital-free days through day 28\|Ventilator-free days through day 28\|Respiratory failure-free days through day 28
NCT04581954	Inflammatory Signal Inhibitors for COVID-19 (MATIS)	Recruiting	Phase 1\|Phase 2	Oct/02/2020	Dec/01/2021
Alternative id - 20HH5926\|2020-001750-22 Interventions - Drug: Ruxolitinib\|Drug: Fostamatinib\|Other: Standard of care Study type - Interventional Study results - No Results Available Locations - Imperial College Healthcare NHS Trust, London, United Kingdom Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 456 Age - 18 Years and older (Adult, Older Adult) Outcome measures - All-cause mortality\|Number and proportion of patients requiring invasive ventilation\|Number and proportion of patients requiring non-invasive ventilation (CPAP and high flow nasal oxygen)\|Number and proportion of patients requiring invasive ventilation or extracorporeal membrane oxygenation (ECMO)\|Number and proportion of patients requiring non-invasive ventilation including continuous positive airway pressure (CPAP) or high flow nasal oxygen\|Number and proportion of patients requiring renal replacement therapy\|Number and proportion of patients experiencing venous thromboembolism events\|Length of stay\|Number and proportion of serious adverse events and discontinuations\|Absolute change in pneumonia severity on the modified WHO COVID-19 Ordinal Scale

Export (.csv)